Cascade Testing in Families With Newly Diagnosed Hereditary Breast and Ovarian Cancer Syndrome

Active, not recruiting

• Conditions: BRCA-Mutated Ovarian Carcinoma; BRIP1 Gene Mutation; EPCAM; MSH2 A636P; RAD51C Gene Mutation; MLH1 Gene Mutation; MSH6 Gene Mutation; PMS2 Gene Mutation
• Interventions: Other: CASCADE genetic screening

• Registration Number: NCT04009148
• Lead Sponsor: NYU Langone Health

Brief Summary

Identification of BRCA mutations in ovarian cancer patients may help guide cancer therapies, prognosis, post-operative screening, and other preventative treatments beyond the initial diagnosis. Likewise, genetic testing of ovarian cancer patients for these germline mutations provides invaluable information for families regarding cancer risk, genetic testing, and subsequently indication for risk-reducing surgery. Cascade testing provides a unique opportunity to identify carriers of a deleterious BRCA mutation which can allow for surgical and chemoprevention of prevention of ovarian cancer. There is currently no literature on the rates of referral for the family members.

Detailed Description

The objective of this study is to perform a pilot study, offering referral to a genetic counseling and genetic testing for family members of a probands known to have a mutation in BRCA1 or BRCA2. In addition to BRCA1 and BRCA2, the NCCN suggests consideration of risk-reducing surgery for mutations in BRIP1, MSH2, MLH1, MSH6, PMS2, EPCAM, RAD51C, RAD51D, investigators will include these subjects as well in the study.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2019-03-01
• Study First Submitted: 2019-07-02
• Study First Submitted QC: 2019-07-02
• Study First Posted: 2019-07-05
• Status Verified: 2024-07
• Primary Completion: 2024-07-22
• Last Update Submitted: 2024-07-22
• Last Update Posted: 2024-07-23
• Study Completion: 2026-10-30

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

• All subjects must have a diagnosis of epithelial ovarian cancer, Fallopian tube caner or primary peritoneal cancer with a known pathogenic genetic mutation.
• All subjects must agree to participate.
• All subjects must have first or second degree relatives who have not been diagnosed with the same genetic mutation.
• A previous diagnosis of cancer in the subject's first or second degree relative is allowed.

Read More

Exclusion Criteria

• Subjects whose first and/or second degree relatives have already been tested with the subject's known mutations, and no other viable family members are available for testing.

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Successful Cascade Testing	CASCADE genetic screening	Genetic counselor contacts relatives and offers participation in study. Relative accepts and genetic testing in performed.
Relative Declines Genetic Testing	CASCADE genetic screening	Genetic counselor contacts relatives and offers participation in study. Relative declines and genetic testing is not performed.

Primary Outcome Measures

Name	Time	Method
Establishing the CASCADE Cohort	1 Year	Number of relatives with successful cascade testing

Trial Locations

Locations (1)

NYU Langone Health; 🇺🇸 New York, New York, United States